Back Back
Cell No. : Cell Name
RCB1695 : RMS-YM  update : 2022/04/15
CommentEmbryonal rhabdomyosarcoma cell line derived from human. Transplantable in nude mouse.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Naoe, Tomoki
Originator Kubo, Kazuaki
Year of deposit 2000
Animal human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 2 years
Tissue urachus
Disease name embryonal rhabdomyosarcoma
Classification cancer
Year of origin 1988
Lifespan infinite
Morphology fibroblast-like
Cellosaurus(Expasy) CVCL_A792
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 20mM HEPES + 10% FBS (heat inactivated) + 0.1mM NEAA
Antibiotics Free
Passage method 0.25% Trypsin + 0.02% EDTA
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 52-55(50) : 52(2),53(18),54(26),55(4)
STR(human) OK
Reference information Reference 1
User's Publication 7

To topTop
2833  Kubo K, Naoe T, Utsumi KR, Ishiguro Y, Ueda K, Shiku H, Yamada K  Cytogenetic and cellular characteristics of a human embryonal rhabdomyosarcoma cell line, RMS-YM.  Br J Cancer  1991  63:879-84  PubMed ID: 1906291  

To topTop
User's Publication
20470  Sun J, Lin W, Li C, Ueki H, Xue R, Sadahira T, Hu H, Wada K, Li N, Liu C, Araki M, Xu A, Huang P.  Repurposing of posaconazole as a hedgehog/SMO signaling inhibitor for embryonal rhabdomyosarcoma therapy.  Am J Cancer Res  2021  11(9):4528-4540  PubMed ID: 34659903  
13046  Ouchi K, Miyachi M, Yagyu S, Kikuchi K, Kuwahara Y, Tsuchiya K, Iehara T, Hosoi H.  Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.  Cancer Cell Int  2020    PubMed ID: 32489328   DOI: 10.1186/s12935-020-01282-z
13338  Sugito N, Heishima K, Ito Y, Akao Y.  Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3-FOXO1.  Cancers (Basel)  2020    PubMed ID: 33182548   DOI: 10.3390/cancers12113312
16817  Kasahara Y, Shin C, Kubo N, Mihara K, Iwabuchi H, Takachi T, Imamura M, Saitoh A, Imai C.  Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity  Clin Transl Immunology  2020  9(7):e1147  PubMed ID: 32670576   DOI: 10.1002/cti2.1147
7155  Kuda M, Kohashi K, Yamada Y, Maekawa A, Kinoshita Y, Nakatsura T, Iwamoto Y, Taguchi T, Oda Y.  FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.  Tumour Biol.  2016  37:5213-23  PubMed ID: 26553361   DOI: 10.1007/s13277-015-4351-9
9540  Zenitani M, Nojiri T, Uehara S, Miura K, Hosoda H, Kimura T, Nakahata K, Miyazato M, Okuyama H, Kangawa K.  C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells.  Cancer Med  2016  5:795-805  PubMed ID: 26816265   DOI: 10.1002/cam4.642
13763  Nagao H, Setoguchi T, Kitamoto S, Ishidou Y, Nagano S, Yokouchi M, Abematsu M, Kawabata N, Maeda S, Yonezawa S, Komiya S.  RBPJ is a novel target for rhabdomyosarcoma therapy  PLoS One  2012  7(7):e39268.  PubMed ID: 22792167   DOI: 10.1371/journal.pone.0039268

Back Back Return Top Page